93
Participants
Start Date
September 14, 2022
Primary Completion Date
September 30, 2029
Study Completion Date
September 30, 2036
Naxitamab
Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
RECRUITING
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RECRUITING
Virginia Commonwealth University, Richmond
WITHDRAWN
Wake Forest University Health Sciences, Winston-Salem
RECRUITING
Levine Children's Hospital, Charlotte
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Augusta University Health, Augusta
RECRUITING
University of Florida, Gainesville
RECRUITING
Arnold Palmer Hospital for Children, Orlando
RECRUITING
Nicklaus Children's Miami, Miami
RECRUITING
University of Alabama, Children's Alabama, Birmingham
RECRUITING
Kentucky Children's Hospital, Lexington
RECRUITING
Children's Hospital and Clinics of Minnesota, Minneapolis
RECRUITING
Cardinal Glennon Children's Hospital, St Louis
RECRUITING
Arkansas Children's Hospital, Little Rock
RECRUITING
Dell Children's Blood and Cancer Center, Austin
RECRUITING
Rady Children's Hospital, San Diego
RECRUITING
UCSF Benioff Children's Hospital Oakland-, Oakland
RECRUITING
Kapiolani Medical Center for Women and Children, Honolulu
RECRUITING
Randall Children's Hospital, Portland
RECRUITING
Connecticut Children's Hospital, Hartford
RECRUITING
UHC Sainte-Justine, Montreal
RECRUITING
CHUQ, Québec
RECRUITING
CIUSSS de l'Estrie-CHUS, Sherbrooke
Collaborators (1)
Y-mAbs Therapeutics
INDUSTRY
Giselle Sholler
OTHER